Compare RBLX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBLX | UTHR |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 23.1B |
| IPO Year | 2020 | 1999 |
| Metric | RBLX | UTHR |
|---|---|---|
| Price | $37.41 | $530.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 14 |
| Target Price | $115.30 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 12.5M | 426.1K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 13.07 |
| Revenue | ★ $2,225,052,000.00 | $1,483,300,000.00 |
| Revenue This Year | $69.69 | $6.39 |
| Revenue Next Year | $19.74 | $14.18 |
| P/E Ratio | ★ N/A | $41.23 |
| Revenue Growth | ★ 15.94 | 2.38 |
| 52 Week Low | $33.88 | $292.34 |
| 52 Week High | $142.00 | $609.35 |
| Indicator | RBLX | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 48.39 |
| Support Level | $33.88 | $526.30 |
| Resistance Level | $59.55 | $542.66 |
| Average True Range (ATR) | 2.68 | 13.95 |
| MACD | -1.28 | 1.68 |
| Stochastic Oscillator | 17.66 | 77.56 |
Roblox operates a free-to-play online video game platform with nearly 125 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators—spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.